C - Reactive Protein Test (CRP) Market Overview
The global C-reactive protein testing market size was estimated at USD 5.34 billion in 2025 and is projected to reach USD 6.08 billion by 2033, growing at a CAGR of 1.68% from 2026 to 2033.
C - Reactive Protein Test (CRP) Market Summary and Scope
| Metrics | Details |
| Market CAGR | 1.68% |
| Segments Covered | By Assay Type, By Detection Type, By Disease Area, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More: Download Sample
C - Reactive Protein Test (CRP) Market Dynamics and Trends
The growing popularity of testing methods is expected to drive the market's growth.
Point-of-care (POC) based testing methods have recently attained massive popularity as these tests provide rapid and accurate results in minimal time. Moreover, these tests can also be easily used in a wide range of healthcare settings. For instance, Abbott's Afinion POC and NycoCard CRP testing methods are suitable for hospital use in the intensive care unit, emergency room, rheumatology, oncology, hematology, and pediatric units of hospitals well as in primary care. Thus, the growing popularity of testing methods is expected to drive the market's growth from the above statements.
The market is expected to hamper due to the availability of alternative treatments with higher accuracy.
CRP High Sensitivity (CRPHS) is a test that measures CRP at low levels. When assessing baseline (i.e., normal) values, CRPHS is more exact than standard CRP, allowing for a measure of chronic inflammation. Moreover, lack of qualified specialists, low demand for C-reactive protein tests compared to other blood tests, and concerns about bad reactions are some factors that the market is expected to get hampered in the forecast period.
C - Reactive Protein Test (CRP) Market Segmentation Analysis
The immunoturbidimetric assay segment is expected to hold the largest market share in the C-reactive protein test (CRP) market.
The immunoturbidimetric assay segment accounted for the largest market share . The wide availability of advanced C-reactive protein determining systems, such as immunoturbidimetric technique-based POC devices and latex-enhanced, high sensitivity systems, attributes to its large revenue share. For instance, Aidan's QuikRead CRP is a rapid and straightforward immunoturbidimetric technique-based POC testing method that determines the protein concentration to support infectious disease diagnosis. Moreover, this essay type offers several advantages, including high speed, ease of automation, and good precision, increasing demand in this segment. In addition, technological advances in immunoturbidimetric tests are projected to drive market expansion in the coming years. Researchers worldwide are working to create advanced and creative assays that will allow for speedy and accurate CRP testing.
the hs-CRP test type segment is expected to hold the largest market share in the C-reactive protein test (CRP) market.
The hs-CRP test type segment accounted for the largest market share. It is attributed to its higher sensitivity than traditional testing methods. It precisely measures low C-reactive protein levels to determine inflammatory levels. Moreover, these characteristics have made determining the risk of cardiovascular disease in healthy patients simple. Besides, current research studies on this test are likely to boost its application in clinical diagnostics, resulting in higher revenue generation in this market.
Furthermore, multiple research studies have demonstrated that hs-CRP assays are increasingly being employed as a marker for various medical disorders, including hypertension, malaria, cancer, and bone illnesses, promoting the adoption of this segment over the others. As a result, the hs-CRP test type is predicted to hold the largest market share in the forecast period.
The cardiovascular disease segment is expected to hold the largest market share in the C-reactive protein test (CRP) market.
The cardiovascular diseases (CVD) segment accounted for the largest market share. It is attributed to the rising incidence of CVD globally, increasing the demand for C-reactive protein testing. Moreover, the high incidence rate boosts clinicians to implement C-reactive protein testing on a large scale.
Moreover, the increase in CVD cases helps researchers conduct numerous investigational studies for examining the role of testing C-reactive protein in CVD, thereby improving the segment revenue generation.Thus, from the above statements, the cardiovascular diseases segment holds the largest market share.
C - Reactive Protein Test (CRP) Market Geographical Share
North America region holds the largest market share in the global C-reactive protein test (CRP) market
North America accounted for the highest revenue share. Established players, technological advancements, well-established healthcare infrastructure, and a well-established reimbursement scenario are some of the factors the region is expected to boost in the forecast period. For instance, BlueCross BlueShield of North Carolina covers CRP measurement in diagnosing inflammatory illnesses as part of its general inflammation testing coverage. According to the Centers for Disease Control and Prevention, CHD also caused 365,744 deaths in the United States in 2018. CHD, on the other hand, claimed the lives of almost 370,900 people this year. Furthermore, the market is predicted to grow in the coming years due to increased public awareness of testing and testing technologies in healthcare. Therefore, from the above statements, the market is expected to boost in the forecast period.
C - Reactive Protein Test (CRP) Companies and Competitive Landscape
Major key players in the C-reactive protein test market include Abbott Laboratories, F. Hoffmann-La Roche AG, Merck KGaA, Randox Laboratories Ltd., BODITECH MED INC., Abaxis, Inc., Thermo Fisher Scientific, Inc., Siemens, Laboratory Corporation of America Holdings, and Beckman Coulter Inc. (Danaher Corporation).
Recent Development-
- February 2026: F. Hoffmann-La Roche Ltd expanded its Cobas diagnostic platform menu globally with enhanced CRP and hs-CRP assays, focusing on integrated testing solutions for infection, sepsis, and cardiovascular disease monitoring.
- January 2026: Abbott Laboratories expanded its point-of-care diagnostics portfolio by enhancing its Afinion CRP testing system, focusing on faster turnaround times for primary care and emergency settings, supporting rapid inflammation detection and infection management.
- November 2025: Thermo Fisher Scientific introduced advanced high-sensitivity CRP (hs-CRP) assay kits designed for cardiovascular risk assessment, improving detection accuracy for low-level inflammation in clinical laboratories.
